FDA Arthritis Drug Advisory Committee
Executive Summary
Ciba-Geigy's Voltaren NDA is on the agenda for the panel's May 16-17 meeting. The panel will also review the status of revised guidelines for the clinical evaluation of NSAIDs. McNeil Labs will also report on a follow-up program on the long-term effects of Suprol. Merck's Clinoril is also on the agenda. The committee will meet in FDA's Parklawn conference rooms D & E 8:30 a.m. both days.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.